
[JPM] Manuscript ID: jpm-977105 - Assistant Editor Assigned

1 message

Daria Dou <daria.dou@mdpi.com>

Fri, Oct 9, 2020 at 6:08 PM

Reply-To: daria.dou@mdpi.com

To: "Muh. Akbar Bahar" <akbarbahar@unhas.ac.id>

Cc: Daria Dou <daria.dou@mdpi.com>, Pauline Lanting <p.lanting@umcg.nl>, "Jens H.J. Bos" <h.j.bos@rug.nl>, "Rolf H. Sijmons" <r.h.sijmons@umcg.nl>, Eelko Hak <e.hak@rug.nl>, Bob Wilffert <b.wilffert@rug.nl>, JPM Editorial Office <jpm@mdpi.com>

Dear Dr. Bahar,

Your manuscript has been assigned to Daria Dou for further processing who will act as a point of contact for any questions related to your paper.

Journal: Journal of Personalized Medicine

Manuscript ID: jpm-977105

Title: Impact of drug-gene-interaction, drug-drug-interaction, and drug-drug-gene-interaction on (es)citalopram therapy: the PharmLines initiative.

Authors: Muh. Akbar Bahar *, Pauline Lanting , Jens H.J. Bos , Rolf H. Sijmons , Eelko Hak , Bob Wilffert

Received: 09 October 2020

E-mails: akbarbahar@unhas.ac.id, p.lanting@umcg.nl, h.j.bos@rug.nl, r.h.sijmons@umcg.nl, e.hak@rug.nl, b.wilffert@rug.nl

You can find it here:

https://susy.mdpi.com/user/manuscripts/review_info/4c59937323f3834b5f04b67ce330446a

Best regards,

Ms. Daria Dou

E-Mail: daria.dou@mdpi.com

--

MDPI Tianjin Office 170 North Road, Room 1804, Block A, Lujiazui Financial Plaza, Hongqiao District, China

MDPI JPM Editorial Office

St. Alban-Anlage 66, 4052 Basel, Switzerland

E-Mail: jpm@mdpi.com

<http://www.mdpi.com/journal/jpm>

[JPM] Manuscript ID: jpm-977105 - Submission Received

5 messages

Editorial Office <jpm@mdpi.com>

Fri, Oct 9, 2020 at 4:41 PM

Reply-To: jpm@mdpi.com

To: "Muh. Akbar Bahar" <akbarbahar@unhas.ac.id>

Cc: Pauline Lanting <p.lanting@umcg.nl>, "Jens H.J. Bos" <h.j.bos@rug.nl>, "Rolf H. Sijmons" <r.h.sijmons@umcg.nl>, Eelko Hak <e.hak@rug.nl>, Bob Wilffert <b.wilffert@rug.nl>

Dear Dr. Bahar,

Thank you very much for uploading the following manuscript to the MDPI submission system. One of our editors will be in touch with you soon.

Journal name: Journal of Personalized Medicine

Manuscript ID: jpm-977105

Type of manuscript: Article

Title: Impact of drug-gene-interaction, drug-drug-interaction, and drug-drug-gene-interaction on (es)citalopram therapy: the PharmLines initiative.

Authors: Muh. Akbar Bahar *, Pauline Lanting, Jens H.J. Bos, Rolf H. Sijmons, Eelko Hak, Bob Wilffert

Received: 9 October 2020

E-mails: akbarbahar@unhas.ac.id, p.lanting@umcg.nl, h.j.bos@rug.nl,

r.h.sijmons@umcg.nl, e.hak@rug.nl, b.wilffert@rug.nl

Submitted to section: Pharmacogenetics,

<https://www.mdpi.com/journal/jpm/sections/pharmacogenetics>

Pharmacogenetics to Avoid Adverse Drug Reactions

https://www.mdpi.com/journal/jpm/special_issues/Pharmacogenetics_Adverse_Drug_Reactions

You can follow progress of your manuscript at the following link (login required):

https://susy.mdpi.com/user/manuscripts/review_info/4c59937323f3834b5f04b67ce330446a

The following points were confirmed during submission:

1. JPM is an open access journal with publishing fees of 1400 CHF for an accepted paper (see <https://www.mdpi.com/about/apc/> for details). This manuscript, if accepted, will be published under an open access Creative Commons CC BY license (<https://creativecommons.org/licenses/by/4.0/>), and I agree to pay the Article Processing Charges as described on the journal webpage (<https://www.mdpi.com/journal/jpm/apc>). See <https://www.mdpi.com/about/openaccess> for more information about open access publishing.

Please note that you may be entitled to a discount if you have previously received a discount code or if your institute is participating in the MDPI Institutional Open Access Program (IOAP), for more information see <https://www.mdpi.com/about/ioap>. If you have been granted any other special discounts for your submission, please contact the JPM editorial office.

2. I understand that:

a. If previously published material is reproduced in my manuscript, I will provide proof that I have obtained the necessary copyright permission. (Please refer to the Rights & Permissions website: <https://www.mdpi.com/authors/rights>).

b. My manuscript is submitted on the understanding that it has not been published in or submitted to another peer-reviewed journal. Exceptions to this rule are papers containing material disclosed at conferences. I confirm that I will inform the journal editorial office if this is the case for my manuscript. I confirm that all authors are familiar with and agree with submission of the contents of the manuscript. The journal editorial office reserves the right to contact all authors to confirm this in case of doubt. I will provide email addresses for all authors and an institutional e-mail address for at least one of the co-authors, and specify the name, address and e-mail for invoicing purposes.

If you have any questions, please do not hesitate to contact the JPM editorial office at jpm@mdpi.com

Kind regards,

JPM Editorial Office

St. Alban-Anlage 66, 4052 Basel, Switzerland

E-Mail: jpm@mdpi.com

Tel. +41 61 683 77 34

Fax: +41 61 302 89 18

*** This is an automatically generated email ***

[JPM] Manuscript ID: jpm-977105 - Ethic Approval Code and Written Informed Consent

3 messages

daria.dou@mdpi.com <daria.dou@mdpi.com>

Fri, Oct 9, 2020 at 6:14 PM

To: "Muh. Akbar Bahar" <akbarbahar@unhas.ac.id>

Cc: jpm@mdpi.com, Pauline Lanting <p.lanting@umcg.nl>, "Jens H.J. Bos" <h.j.bos@rug.nl>, "Rolf H. Sijmons" <r.h.sijmons@umcg.nl>, Eelko Hak <e.hak@rug.nl>, Bob Wilffert <b.wilffert@rug.nl>

Dear Dr. Bahar,

Thank you very much for submitting your manuscript to Journal of Personalized Medicine.

Please provide the ethical approval code in the attached version and send us the informed consent for publication.

1. As your original descriptions of research conducted in human beings contained in your manuscript, you should provide the details of approval by a properly constituted research ethics committee. As a minimum, the project identification code and name of the ethics committee or institutional review board should be cited in the Methods section. Please also confirm whether the paper follows the rules of the Declaration of Helsinki.

2. Except for the above point, a written informed consent for publication (private information identifying participants need not be included) is also required and please state "Anyone involved in the research agrees to participate and agrees to have details the results of the research about them published" in the methods section. Enclosed we attached a written informed consent template for your reference.

We are looking forward to hearing from you soon.

Kind regards,
Daria

Ms. Daria Dou
Assistant Editor
E-mail: daria.dou@mdpi.com
Journal of Personalized Medicine (<http://www.mdpi.com/journal/jpm>)
Twitter: @JPM_MDPI

We are pleased to announce that JPM's first Impact Factor is 4.433 (Journal Citation Reports, 2019 Edition). JPM now ranks 10/102 (Q1) in the category "Health Care Sciences & Services", and 24/165 (Q1) in the category "Medicine, General & Internal".

On 2020/10/9 18:08, Daria Dou wrote:

Dear Dr. Bahar,

Your manuscript has been assigned to Daria Dou for further processing who will act as a point of contact for any questions related to your paper.

Journal: Journal of Personalized Medicine
Manuscript ID: jpm-977105
Title: Impact of drug-gene-interaction, drug-drug-interaction, and drug-drug-gene-interaction on (es)citalopram therapy: the PharmLines initiative.
Authors: Muh. Akbar Bahar *, Pauline Lanting , Jens H.J. Bos , Rolf H. Sijmons , Eelko Hak , Bob Wilffert

Received: 09 October 2020
E-mails: akbarbahar@unhas.ac.id, p.lanting@umcg.nl, h.j.bos@rug.nl, r.h.sijmons@umcg.nl, e.hak@rug.nl, b.wilffert@rug.nl

You can find it here:
https://susy.mdpi.com/user/manuscripts/review_info/4c59937323f3834b5f04b67ce330446a

Best regards,
Ms. Daria Dou
E-Mail: daria.dou@mdpi.com

--
MDPI Tianjin Office 170 North Road, Room 1804, Block A, Lujiazui Financial Plaza, Hongqiao District, China

MDPI JPM Editorial Office
St. Alban-Anlage 66, 4052 Basel, Switzerland
E-Mail: jpm@mdpi.com
<http://www.mdpi.com/journal/jpm>

Muh. Akbar Bahar <akbarbahar@unhas.ac.id>

Fri, Oct 9, 2020 at 6:41 PM

To: "daria.dou@mdpi.com" <daria.dou@mdpi.com>

Cc: JPM Editorial Office <jpm@mdpi.com>, Pauline Lanting <p.lanting@umcg.nl>, "Jens H.J. Bos" <h.j.bos@rug.nl>, "Rolf H. Sijmons" <r.h.sijmons@umcg.nl>, Eelko Hak <e.hak@rug.nl>, Bob Wilffert <b.wilffert@rug.nl>

Dear Ms. Daria Dou,

Thank you for your email.

Since we used databases in our research, could we include the following statement below:

ETHICS STATEMENT

Ethics approval was not needed according to institutional guidelines and national legislation since the data generated in this manuscript relied exclusively on the research databases

with pseudonymized information and informed consent was obtained at the time of original data collection.

Kind regards,

Muh. Akbar Bahar, Ph.D, Apt
Fakultas Farmasi, Universitas Hasanuddin
Makassar, South Sulawesi, Indonesia

[Quoted text hidden]

daria.dou@mdpi.com <daria.dou@mdpi.com>

Sat, Oct 10, 2020 at 8:51 AM

To: "Muh. Akbar Bahar" <akbarbahar@unhas.ac.id>

Cc: jpm@mdpi.com, Pauline Lanting <p.lanting@umcg.nl>, "Jens H.J. Bos" <h.j.bos@rug.nl>, "Rolf H. Sijmons" <r.h.sijmons@umcg.nl>, Eelko Hak <e.hak@rug.nl>, Bob Wilffert <b.wilffert@rug.nl>

Dear Dr. Bahar,

Thanks for your cooperation. We will now process your submission further and will keep you informed about the status of your submission.

Kind regards,
Daria

Ms. Daria Dou
Assistant Editor
E-mail: daria.dou@mdpi.com
Journal of Personalized Medicine (<http://www.mdpi.com/journal/jpm>)
Twitter: @JPM_MDPI

We are pleased to announce that JPM's first Impact Factor is 4.433 (Journal Citation Reports, 2019 Edition). JPM now ranks 10/102 (Q1) in the category "Health Care Sciences & Services", and 24/165 (Q1) in the category "Medicine, General & Internal".

On 2020/10/9 18:41, Muh. Akbar Bahar wrote:

Dear Ms. Daria Dou,

Thank you for your email.

Since we used databases in our research, could we include the following statement below:

ETHICS STATEMENT

Ethics approval was not needed according to institutional guidelines and national legislation since the data generated in this manuscript relied exclusively on the research databases

with pseudonymized information and informed consent was obtained at the time of original data collection.

Kind regards,

Muh. Akbar Bahar, Ph.D, Apt
Fakultas Farmasi, Universitas Hasanuddin
Makassar, South Sulawesi, Indonesia

On Fri, Oct 9, 2020 at 6:14 PM daria.dou@mdpi.com <<mailto:daria.dou@mdpi.com>> <daria.dou@mdpi.com> wrote:

Dear Dr. Bahar,

Thank you very much for submitting your manuscript to Journal of

[JPM] Manuscript ID: jpm-977105 - Article Processing Charge Confirmation - please reply to this email

5 messages

Daria Dou <daria.dou@mdpi.com>

Fri, Oct 9, 2020 at 5:21 PM

Reply-To: daria.dou@mdpi.com

To: "Muh. Akbar Bahar" <akbarbahar@unhas.ac.id>

Cc: JPM Editorial Office <jpm@mdpi.com>

Dear Dr. Bahar,

Thank you very much for submitting your manuscript to Journal of Personalized Medicine:

Journal name: Journal of Personalized Medicine

Manuscript ID: jpm-977105

Type of manuscript: Article

Title: Impact of drug-gene-interaction, drug-drug-interaction, and drug-drug-gene-interaction on (es)citalopram therapy: the PharmLines initiative.

Authors: Muh. Akbar Bahar *, Pauline Lanting, Jens H.J. Bos, Rolf H. Sijmons, Eelko Hak, Bob Wilffert

Received: 9 October 2020

E-mails: akbarbahar@unhas.ac.id, p.lanting@umcg.nl, h.j.bos@rug.nl, r.h.sijmons@umcg.nl, e.hak@rug.nl, b.wilffert@rug.nl

Submitted to section: Pharmacogenetics,

<https://www.mdpi.com/journal/jpm/sections/pharmacogenetics>

Pharmacogenetics to Avoid Adverse Drug Reactions

https://www.mdpi.com/journal/jpm/special_issues/Pharmacogenetics_Adverse_Drug_Reactions

We confirm that, if accepted for publication, the following Article Processing Charges (APC), 1260 CHF, will apply to your article:

Journal APC: 1400 CHF

Institutional Open Access Program (IOAP): University of Groningen

IOAP Discount: 10%

Total APC: 1260 CHF

Please note that you may be entitled to a discount if you have previously received a discount code. Also note that reviewer vouchers must be applied before acceptance for publication. Vouchers can no longer be applied once an APC invoice has been issued. Reviewer vouchers, IOAP discounts, and vouchers offered by the Editorial Office cannot be applied to one invoice at the same time. You need to select one type of voucher to use. If you need to add any discount or replace the current discount with another type of discount, please contact the JPM Editorial Office as soon as possible.

Please confirm that you support open access publishing, which allows unlimited access to your published paper and that you will pay the Article Processing Charge if your manuscript is accepted.

Thank you in advance for your cooperation. I look forward to hearing from you.

Kind regards,

Ms. Daria Dou

E-Mail: daria.dou@mdpi.com

--

MDPI Tianjin Office 170 North Road, Room 1804, Block A, Lujiazui Financial Plaza, Hongqiao District, China

MDPI JPM Editorial Office

St. Alban-Anlage 66, 4052 Basel, Switzerland

E-Mail: jpm@mdpi.com

<http://www.mdpi.com/journal/jpm>

Muh. Akbar Bahar <akbarbahar@unhas.ac.id>

Fri, Oct 9, 2020 at 5:39 PM

To: daria.dou@mdpi.com

Cc: JPM Editorial Office <jpm@mdpi.com>

Dear Ms. Daria Dou,

Thank you for your email.

Previously i got an invitation email to submit a paper in the JPM as below:

Dear Dr. Bahar,

I am guest editing a Special Issue for the Journal of Personalized Medicine on "Pharmacogenetics to Avoid Adverse Drug Reactions". Due to your expertise on this field we think you can make an excellent contribution to the issue, writing an article or a review on the

topic. Thus, we would like to invite you to submit a manuscript.

For more information, please visit the following link:

https://www.mdpi.com/journal/jpm/special_issues/Pharmacogenetics_Adverse_Drug_Reactions

JPM is an international, open access, peer-reviewed, fully open-access journal. It is indexed by PubMed, Scopus (CiteScore of 3.59), and Web Of Science (Impact Factor of 4.433).

The submission deadline is **15 March 2021**. You may send your manuscript now or up until the deadline as they will be published on an ongoing basis after being peer-reviewed.

As an invited paper, we offer you the privilege to enjoy 10% percent on publication fee.

In case you need any further information, please never hesitate to contact me or the JPM editor Sera Li (sera.li@mdpi.com).

Kind regards,

Dr. Luis A. López-Fernández

Guest Editor

Therefore, if it is possible i will use the discount above. We will pay the APC once our manuscript is accepted.

Kind regards,

Muh. Akbar Bahar, Ph.D, Apt
Fakultas Farmasi, Universitas Hasanuddin
Makassar, South Sulawesi, Indonesia

[Quoted text hidden]

daria.dou@mdpi.com <daria.dou@mdpi.com>
To: "Muh. Akbar Bahar" <akbarbahar@unhas.ac.id>
Cc: jpm@mdpi.com

Sat, Oct 10, 2020 at 9:55 AM

Dear Dr. Bahar,

Thank you for your email. Journal of Personalized Medicine is an international peer-reviewed open access quarterly journal published by MDPI. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs).

IOAP discounts, and vouchers offered by the Editorial Office cannot be applied to one invoice at the same time.

If you choose IOAP discount, the following Article Processing Charges (APC), 1260 CHF, will apply to your article:
Journal APC: 1400 CHF
Institutional Open Access Program (IOAP): University of Groningen
IOAP Discount: 10%
Total APC: 1260 CHF

If you choose voucher, the following Article Processing Charges (APC), 1260 CHF, will apply to your article:
Journal APC: 1400 CHF
10% discount by invited: 140 CHF
Total APC: 1260 CHF

Both discounts enjoy the same price. Please reply us at your earliest convenience. Thank you for your cooperation.

I look forward to hearing from you.

Kind regards,
Daria

Ms. Daria Dou
Assistant Editor
E-mail: daria.dou@mdpi.com
Journal of Personalized Medicine (<http://www.mdpi.com/journal/jpm>)
Twitter: @JPM_MDPI

We are pleased to announce that JPM's first Impact Factor is 4.433 (Journal Citation Reports, 2019 Edition). JPM now ranks 10/102 (Q1) in the category "Health Care Sciences & Services", and 24/165 (Q1) in the category "Medicine, General & Internal".

On 2020/10/9 17:39, Muh. Akbar Bahar wrote:

Dear Ms. Daria Dou,

Thank you for your email.

Previously i got an invitation email to submit a paper in the JPM as below:

Dear Dr. Bahar,

I am guest editing a Special Issue for the Journal of Personalized Medicine on "Pharmacogenetics to Avoid Adverse Drug Reactions". Due to your expertise on this field we think you can make an excellent contribution to the issue, writing an article or a review on the topic. Thus, we would like to invite you to submit a manuscript.

For more information, please visit the following link:

https://www.mdpi.com/journal/jpm/special_issues/Pharmacogenetics_Adverse_Drug_Reactions

JPM is an international, open access, peer-reviewed, fully open-access journal. It is indexed by PubMed, Scopus (CiteScore of 3.59), and Web Of Science (Impact Factor of 4.433).

The submission deadline is *15 March 2021*. You may send your manuscript now or up until the deadline as they will be published on an ongoing basis after being peer-reviewed.

As an invited paper, we offer you the privilege to enjoy 10% percent on publication fee.

In case you need any further information, please never hesitate to contact me or the JPM editor Sera Li (sera.li@mdpi.com <<mailto:sera.li@mdpi.com>>).

Kind regards,

Dr. Luis A. López-Fernández

/Guest Editor/

Therefore, if it is possible i will use the discount above. We will pay the APC once our manuscript is accepted.

Kind regards,

Muh. Akbar Bahar, Ph.D, Apt
Fakultas Farmasi, Universitas Hasanuddin
Makassar, South Sulawesi, Indonesia

On Fri, Oct 9, 2020 at 5:21 PM Daria Dou <daria.dou@mdpi.com <<mailto:daria.dou@mdpi.com>>> wrote:

Dear Dr. Bahar,

Thank you very much for submitting your manuscript to Journal of Personalized Medicine:

Journal name: Journal of Personalized Medicine
Manuscript ID: jpm-977105
Type of manuscript: Article
Title: Impact of drug-gene-interaction, drug-drug-interaction, and drug-drug-gene-interaction on (es)citalopram therapy: the PharmLines initiative.
Authors: Muh. Akbar Bahar *, Pauline Lanting, Jens H.J. Bos, Rolf H. Sijmons, Eelko Hak, Bob Wilffert
Received: 9 October 2020
E-mails: akbarbahar@unhas.ac.id <<mailto:akbarbahar@unhas.ac.id>>, p.lanting@umcg.nl <<mailto:p.lanting@umcg.nl>>, h.j.bos@rug.nl <<mailto:h.j.bos@rug.nl>>, r.h.sijmons@umcg.nl <<mailto:r.h.sijmons@umcg.nl>>, e.hak@rug.nl <<mailto:e.hak@rug.nl>>, b.wilffert@rug.nl <<mailto:b.wilffert@rug.nl>>

[Quoted text hidden]

E-Mail: daria.dou@mdpi.com <<mailto:daria.dou@mdpi.com>>

--
MDPI Tianjin Office 170 North Road, Room 1804, Block A, Lujiazui Financial Plaza, Hongqiao District, China

MDPI JPM Editorial Office
St. Alban-Anlage 66, 4052 Basel, Switzerland
E-Mail: jpm@mdpi.com <<mailto:jpm@mdpi.com>>
<http://www.mdpi.com/journal/jpm>

Dear Ms. Daria Dou,

Thank you for your email I will choose to use the voucher then.

Kind regards,
Muh. Akbar Bahar, Ph.D, Apt
Fakultas Farmasi, Universitas Hasanuddin
Makassar, South Sulawesi, Indonesia

[Quoted text hidden]

daria.dou@mdpi.com <daria.dou@mdpi.com>
To: "Muh. Akbar Bahar" <akbarbahar@unhas.ac.id>
Cc: jpm@mdpi.com

Mon, Oct 12, 2020 at 8:59 AM

Dear Dr. Bahar,

Thank you very much for your confirmation. We will now process your submission further and will keep you informed about the status of your submission.

Kind regards,
Daria

Ms. Daria Dou
Assistant Editor
E-mail: daria.dou@mdpi.com
Journal of Personalized Medicine (<http://www.mdpi.com/journal/jpm>)
Twitter: @JPM_MDPI

We are pleased to announce that JPM's first Impact Factor is 4.433 (Journal Citation Reports, 2019 Edition). JPM now ranks 10/102 (Q1) in the category "Health Care Sciences & Services", and 24/165 (Q1) in the category "Medicine, General & Internal".

On 2020/10/10 10:42, Muh. Akbar Bahar wrote:

Dear Ms. Daria Dou,

Thank you for your email I will choose to use the voucher then.

Kind regards,
Muh. Akbar Bahar, Ph.D, Apt
Fakultas Farmasi, Universitas Hasanuddin
Makassar, South Sulawesi, Indonesia

On Sat, Oct 10, 2020 at 9:55 AM daria.dou@mdpi.com <<mailto:daria.dou@mdpi.com>> <daria.dou@mdpi.com> wrote:

Dear Dr. Bahar,

Thank you for your email. Journal of Personalized Medicine is an international peer-reviewed open access quarterly journal published by MDPI. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs).

IOAP discounts, and vouchers offered by the Editorial Office cannot be applied to one invoice at the same time.

If you choose IOAP discount, the following Article Processing Charges (APC), 1260 CHF, will apply to your article:

Journal APC: 1400 CHF
Institutional Open Access Program (IOAP): University of Groningen
IOAP Discount: 10%
Total APC: 1260 CHF

If you choose voucher, the following Article Processing Charges (APC), 1260 CHF, will apply to your article:

Journal APC: 1400 CHF
10% discount by invited: 140 CHF
Total APC: 1260 CHF

Both discounts enjoy the same price. Please reply us at your earliest convenience. Thank you for your cooperation.

I look forward to hearing from you.

Kind regards,
Daria

Ms. Daria Dou
Assistant Editor
E-mail: daria.dou@mdpi.com <<mailto:daria.dou@mdpi.com>>

[Quoted text hidden]

> <<mailto:sera.li@mdpi.com> <<mailto:sera.li@mdpi.com>>>).

>
> Kind regards,

> *Dr. Luis A. López-Fernández*

> /Guess Editor/
>
> -----

> Therefore, if it is possible i will use the discount above. We
will pay

> the APC once our manuscript is accepted.
>
>

> Kind regards,
>
>

> Muh. Akbar Bahar, Ph.D, Apt
> Fakultas Farmasi, Universitas Hasanuddin
> Makassar, South Sulawesi, Indonesia
>
>

> On Fri, Oct 9, 2020 at 5:21 PM Daria Dou <daria.dou@mdpi.com
<<mailto:daria.dou@mdpi.com>>

> <<mailto:daria.dou@mdpi.com> <<mailto:daria.dou@mdpi.com>>>> wrote:

> Dear Dr. Bahar,

> Thank you very much for submitting your manuscript to Journal of
> Personalized
> Medicine:

> Journal name: Journal of Personalized Medicine

> Manuscript ID: jpm-977105

> Type of manuscript: Article

> Title: Impact of drug-gene-interaction,

drug-drug-interaction, and

> drug-drug-gene-interaction on (es)citalopram therapy: the

PharmLines

> initiative.

> Authors: Muh. Akbar Bahar *, Pauline Lanting, Jens H.J. Bos,

Rolf H.

> Sijmons,

> Eelko Hak, Bob Wilffert

> Received: 9 October 2020

> E-mails: akbarbahar@unhas.ac.id

<<mailto:akbarbahar@unhas.ac.id>> <<mailto:akbarbahar@unhas.ac.id>>

<<mailto:akbarbahar@unhas.ac.id>>>,
> p.lanting@umcg.nl <<mailto:p.lanting@umcg.nl>>

<<mailto:p.lanting@umcg.nl> <<mailto:p.lanting@umcg.nl>>>,
h.j.bos@rug.nl <<mailto:h.j.bos@rug.nl>>

> <<mailto:h.j.bos@rug.nl> <<mailto:h.j.bos@rug.nl>>>,
> r.h.sijmons@umcg.nl <<mailto:r.h.sijmons@umcg.nl>>

<<mailto:r.h.sijmons@umcg.nl> <<mailto:r.h.sijmons@umcg.nl>>>,
e.hak@rug.nl <<mailto:e.hak@rug.nl>>

> <<mailto:e.hak@rug.nl> <<mailto:e.hak@rug.nl>>>,
b.wilffert@rug.nl <<mailto:b.wilffert@rug.nl>>

<<mailto:b.wilffert@rug.nl> <<mailto:b.wilffert@rug.nl>>>

[Quoted text hidden]

<<mailto:daria.dou@mdpi.com> <<mailto:daria.dou@mdpi.com>>>

>

> --

> MDPI Tianjin Office 170 North Road, Room 1804, Block A, Lujiazui

> Financial

> Plaza, Hongqiao District, China
>

> MDPI JPM Editorial Office

> St. Alban-Anlage 66, 4052 Basel, Switzerland

> E-Mail: jpm@mdpi.com <<mailto:jpm@mdpi.com>>

<<mailto:jpm@mdpi.com> <<mailto:jpm@mdpi.com>>>

> <http://www.mdpi.com/journal/jpm>

>

[JPM] Manuscript ID: jpm-977105 - Major Revisions Due to 30 October 2020

30 messages

Daria Dou <daria.dou@mdpi.com>

Fri, Oct 23, 2020 at 10:25 AM

Reply-To: daria.dou@mdpi.com

To: "Muh. Akbar Bahar" <akbarbahar@unhas.ac.id>

Cc: Pauline Lanting <p.lanting@umcg.nl>, "Jens H.J. Bos" <h.j.bos@rug.nl>, "Rolf H. Sijmons" <r.h.sijmons@umcg.nl>, Eelko Hak <e.hak@rug.nl>, Bob Wilffert <b.wilffert@rug.nl>, JPM Editorial Office <jpm@mdpi.com>

Dear Dr. Bahar,

Thank you for submitting the following manuscript to JPM:

Manuscript ID: jpm-977105

Type of manuscript: Article

Title: Impact of drug-gene-interaction, drug-drug-interaction, and drug-drug-gene-interaction on (es)citalopram therapy: the PharmLines initiative.

Authors: Muh. Akbar Bahar *, Pauline Lanting, Jens H.J. Bos, Rolf H. Sijmons, Eelko Hak, Bob Wilffert

Received: 9 October 2020

E-mails: akbarbahar@unhas.ac.id, p.lanting@umcg.nl, h.j.bos@rug.nl, r.h.sijmons@umcg.nl, e.hak@rug.nl, b.wilffert@rug.nl

Submitted to section: Pharmacogenetics,

<https://www.mdpi.com/journal/jpm/sections/pharmacogenetics>

Pharmacogenetics to Avoid Adverse Drug Reactions

https://www.mdpi.com/journal/jpm/special_issues/Pharmacogenetics_Adverse_Drug_Reactions

It has been reviewed by experts in the field and we request that you make major revisions before it is processed further. Please find your manuscript and the review reports at the following link:

<https://susy.mdpi.com/user/manuscripts/resubmit/4c59937323f3834b5f04b67ce330446a>

Your co-authors can also view this link if they have an account in our submission system using the e-mail address in this message.

Please revise the manuscript according to the reviewers' comments and upload the revised file **within 7 days**. Use the version of your manuscript found at the above link for your revisions, as the editorial office may have made formatting changes to your original submission. Any revisions should be clearly **highlighted**, for example using the ****Track Changes**** function in Microsoft Word, so that changes are easily visible to the editors and reviewers. Please provide **a cover letter** to explain point-by-point the details of the revisions in the manuscript and your responses to the reviewers' comments. Please include in your rebuttal if you found it impossible to address certain comments. The revised version will be inspected by the editors and reviewers. Please detail the revisions that have been made, citing the line number and exact change, so that the editor can check the changes expeditiously. Simple statements like 'done' or 'revised as requested' will not be accepted unless the change is simply a typographical error.

Please carefully read the guidelines outlined in the 'Instructions for Authors' on the journal website <https://www.mdpi.com/journal/jpm/instructions> and ensure that your manuscript resubmission adheres to these guidelines. In particular, please ensure that abbreviations have been defined in parentheses the first time they appear in the abstract, main text, and in figure or table captions; citations within the text are in the correct format; references at the end of the text are in the correct format; figures and/or tables are placed at appropriate positions within the text and are of suitable quality; tables are prepared in MS Word table format, not as images; and permission has been obtained and there are no copyright issues.

If the reviewers have suggested that your manuscript should undergo extensive English editing, please have the English in the manuscript thoroughly checked and edited for language and form. Alternatively, MDPI provides an English editing service checking grammar, spelling, punctuation and some improvement of style where necessary for an additional charge (extensive re-writing is not included), see details at <https://www.mdpi.com/authors/english>.

Please revise manuscript based on the attached word version.

Do not hesitate to contact us if you have any questions regarding the revision of your manuscript or if you need more time. We look forward to hearing from you soon.

Kind regards,

Ms. Daria Dou

E-Mail: daria.dou@mdpi.com

Re: [JPM] Manuscript ID: jpm-977105 - Major Revisions Due to 12 November 2020

3 messages

daria.dou@mdpi.com <daria.dou@mdpi.com>

Wed, Oct 28, 2020 at 12:29 PM

To: "Muh. Akbar Bahar" <akbarbahar@unhas.ac.id>

Cc: jpm@mdpi.com, "E. Hak" <e.hak@rug.nl>, "B. Wilffert" <b.wilffert@rug.nl>, Pauline Lanting <p.lanting@umcg.nl>, "Rolf H. Sijmons" <r.h.sijmons@umcg.nl>

Dear Dr. Bahar,

Thank you very much for your email. We can understand your situation. However, based on our experience, if there is a too long extension, it will not be beneficial for second review and final decision, so we send this email and would like to know the possibility that you submit the revised version before 12 November 2020.

Thank you in advance for your kind cooperation.

Kind regards,
Daria

Ms. Daria Dou
Assistant Editor
E-mail: daria.dou@mdpi.com
Journal of Personalized Medicine (<http://www.mdpi.com/journal/jpm>)
Twitter: @JPM_MDPI

We are pleased to announce that JPM's first Impact Factor is 4.433 (Journal Citation Reports, 2019 Edition). JPM now ranks 10/102 (Q1) in the category "Health Care Sciences & Services", and 24/165 (Q1) in the category "Medicine, General & Internal".

On 2020/10/28 8:03, Muh. Akbar Bahar wrote:

Dear Ms. Daria Dou,

I would like to ask for an extension of the deadline to submit the revised version since the comments from the reviewers are quite hard to handle.

I would like to extend it to 15th Nov 2020, if it is possible.

Thank you very much

Kind regards,

Akbar

On Fri, Oct 23, 2020 at 10:25 AM Daria Dou <daria.dou@mdpi.com <<mailto:daria.dou@mdpi.com>>> wrote:

Dear Dr. Bahar,

Thank you for submitting the following manuscript to JPM:

Manuscript ID: jpm-977105

Type of manuscript: Article

Title: Impact of drug-gene-interaction, drug-drug-interaction, and drug-drug-gene-interaction on (es)citalopram therapy: the PharmLines initiative.

Authors: Muh. Akbar Bahar *, Pauline Lanting, Jens H.J. Bos, Rolf H. Sijmons,

Eelko Hak, Bob Wilffert

Received: 9 October 2020

E-mails: akbarbahar@unhas.ac.id <<mailto:akbarbahar@unhas.ac.id>>,

p.lanting@umcg.nl <<mailto:p.lanting@umcg.nl>>, h.j.bos@rug.nl

<<mailto:h.j.bos@rug.nl>>,

r.h.sijmons@umcg.nl <<mailto:r.h.sijmons@umcg.nl>>, e.hak@rug.nl

<<mailto:e.hak@rug.nl>>, b.wilffert@rug.nl <<mailto:b.wilffert@rug.nl>>

Submitted to section: Pharmacogenetics,

<https://www.mdpi.com/journal/jpm/sections/pharmacogenetics>

Pharmacogenetics to Avoid Adverse Drug Reactions

https://www.mdpi.com/journal/jpm/special_issues/Pharmacogenetics_Adverse_Drug_Reactions

It has been reviewed by experts in the field and we request that you make

major revisions before it is processed further. Please find your manuscript

and the review reports at the following link:

<https://susy.mdpi.com/user/manuscripts/resubmit/4c59937323f3834b5f04b67ce330446a>

Your co-authors can also view this link if they have an account in our submission system using the e-mail address in this message.

Please revise the manuscript according to the reviewers' comments and upload the revised file *within 7 days*. Use the version of your manuscript found at the above link for your revisions, as the editorial office may have made formatting changes to your original submission. Any revisions should be clearly *highlighted*, for example using the ***Track Changes*** function in Microsoft Word, so that changes are easily visible to the editors and reviewers. Please provide *a cover letter* to explain point-by-point the details of the revisions in the manuscript and your responses to the reviewers' comments. Please include in your rebuttal if you found it impossible to address certain comments. The revised version will be inspected by the editors and reviewers. Please detail the revisions that have been made, citing the line number and exact change, so that the editor can check the changes expeditiously. Simple statements like 'done' or 'revised as requested' will not be accepted unless the change is simply a typographical error.

Please carefully read the guidelines outlined in the 'Instructions for Authors' on the journal website <https://www.mdpi.com/journal/jpm/instructions> and ensure that your manuscript resubmission adheres to these guidelines. In particular, please ensure that abbreviations have been defined in parentheses the first time they appear in the abstract, main text, and in figure or table captions; citations within the text are in the correct format; references at the end of the text are in the correct format; figures and/or tables are placed at appropriate positions within the text and are of suitable quality; tables are prepared in MS Word table format, not as images; and permission has been obtained and there are no copyright issues.

If the reviewers have suggested that your manuscript should undergo extensive English editing, please have the English in the manuscript thoroughly checked and edited for language and form. Alternatively, MDPI provides an English editing service checking grammar, spelling, punctuation and some improvement of style where necessary for an additional charge (extensive re-writing is not included), see details at <https://www.mdpi.com/authors/english>.

Please revise manuscript based on the attached word version.

Do not hesitate to contact us if you have any questions regarding the revision of your manuscript or if you need more time. We look forward to hearing from you soon.

Kind regards,
Ms. Daria Dou
E-Mail: daria.dou@mdpi.com <<mailto:daria.dou@mdpi.com>>

--
MDPI Tianjin Office 170 North Road, Room 1804, Block A, Lujiazui Financial Plaza, Hongqiao District, China

MDPI JPM Editorial Office
St. Alban-Anlage 66, 4052 Basel, Switzerland
E-Mail: jpm@mdpi.com <<mailto:jpm@mdpi.com>>
<http://www.mdpi.com/journal/jpm>

Dear Ms. Daria Dou,

Thank you very much for your understanding and the extension. I will try to resubmit it soon before the deadline.

Kind regards,

Akbar

[Quoted text hidden]

daria.dou@mdpi.com <daria.dou@mdpi.com>
To: "Muh. Akbar Bahar" <akbarbahar@unhas.ac.id>
Cc: jpm@mdpi.com

Wed, Oct 28, 2020 at 2:56 PM

Dear Dr. Bahar,

Thanks for your reply. We look forward to receiving your revised manuscript as scheduled.

Kind regards,
Daria

Ms. Daria Dou
Assistant Editor
E-mail: daria.dou@mdpi.com
Journal of Personalized Medicine (<http://www.mdpi.com/journal/jpm>)
Twitter: @JPM_MDPI

We are pleased to announce that JPM's first Impact Factor is 4.433 (Journal Citation Reports, 2019 Edition). JPM now ranks 10/102 (Q1) in the category "Health Care Sciences & Services", and 24/165 (Q1) in the category "Medicine, General & Internal".

On 2020/10/28 13:44, Muh. Akbar Bahar wrote:

Dear Ms. Daria Dou,

Thank you very much for your understanding and the extension. I will try to resubmit it soon before the deadline.

Kind regards,

Akbar

On Wed, Oct 28, 2020 at 12:29 PM daria.dou@mdpi.com <<mailto:daria.dou@mdpi.com>> <daria.dou@mdpi.com> <<mailto:daria.dou@mdpi.com>>> wrote:

Dear Dr. Bahar,

Thank you very much for your email. We can understand your situation. However, based on our experience, if there is a too long extension, it will not be beneficial for second review and final decision, so we send this email and would like to know the possibility that you submit the revised version before 12 November 2020.

Thank you in advance for your kind cooperation.

Kind regards,
Daria

Ms. Daria Dou
Assistant Editor
E-mail: daria.dou@mdpi.com <<mailto:daria.dou@mdpi.com>>
Journal of Personalized Medicine (<http://www.mdpi.com/journal/jpm>)
Twitter: @JPM_MDPI

We are pleased to announce that JPM's first Impact Factor is 4.433 (Journal Citation Reports, 2019 Edition). JPM now ranks 10/102 (Q1) in the category "Health Care Sciences & Services", and 24/165 (Q1) in the category "Medicine, General & Internal".

On 2020/10/28 8:03, Muh. Akbar Bahar wrote:

> Dear Ms. Daria Dou,

>

> I would like to ask for an extension of the deadline to submit the
> revised version since the comments from the reviewers are quite
hard to

> handle.

> I would like to extend it to 15th Nov 2020, if it is possible.

>

> Thank you very much

>

>

> Kind regards,

>
>
>
> Akbar
>
> On Fri, Oct 23, 2020 at 10:25 AM Daria Dou <daria.dou@mdpi.com>
<<mailto:daria.dou@mdpi.com>>
> <<mailto:daria.dou@mdpi.com> <<mailto:daria.dou@mdpi.com>>>> wrote:

>
> Dear Dr. Bahar,
>
> Thank you for submitting the following manuscript to JPM:
>
> Manuscript ID: jpm-977105
> Type of manuscript: Article
> Title: Impact of drug-gene-interaction,
drug-drug-interaction, and
> drug-drug-gene-interaction on (es)citalopram therapy: the
PharmLines
> initiative.
> Authors: Muh. Akbar Bahar *, Pauline Lanting, Jens H.J. Bos,
Rolf H.
> Sijmons,
> Eelko Hak, Bob Wilffert
> Received: 9 October 2020
> E-mails: akbarbahar@unhas.ac.id
<<mailto:akbarbahar@unhas.ac.id>> <<mailto:akbarbahar@unhas.ac.id>>
<<mailto:akbarbahar@unhas.ac.id>>>,
> p.lanting@umcg.nl <<mailto:p.lanting@umcg.nl>>
<<mailto:p.lanting@umcg.nl> <<mailto:p.lanting@umcg.nl>>>,
h.j.bos@rug.nl <<mailto:h.j.bos@rug.nl>>
> <<mailto:h.j.bos@rug.nl> <<mailto:h.j.bos@rug.nl>>>,
> r.h.sijmons@umcg.nl <<mailto:r.h.sijmons@umcg.nl>>
<<mailto:r.h.sijmons@umcg.nl> <<mailto:r.h.sijmons@umcg.nl>>>,
e.hak@rug.nl <<mailto:e.hak@rug.nl>>
> <<mailto:e.hak@rug.nl> <<mailto:e.hak@rug.nl>>>,
b.wilffert@rug.nl <<mailto:b.wilffert@rug.nl>>
<<mailto:b.wilffert@rug.nl> <<mailto:b.wilffert@rug.nl>>>

[Quoted text hidden]

<<mailto:daria.dou@mdpi.com> <<mailto:daria.dou@mdpi.com>>>
>
> --
> MDPI Tianjin Office 170 North Road, Room 1804, Block A, Lujiazui
> Financial
> Plaza, Hongqiao District, China
>
> MDPI JPM Editorial Office
> St. Alban-Anlage 66, 4052 Basel, Switzerland
> E-Mail: jpm@mdpi.com <<mailto:jpm@mdpi.com>>
<<mailto:jpm@mdpi.com> <<mailto:jpm@mdpi.com>>>
> <http://www.mdpi.com/journal/jpm>
>

[JPM] Manuscript ID: jpm-977105 - Manuscript Resubmitted

1 message

Submission System <submission@mdpi.com>

Wed, Nov 11, 2020 at 11:39 AM

Reply-To: Daria Dou <daria.dou@mdpi.com>, JPM Editorial Office <jpm@mdpi.com>

To: "Muh. Akbar Bahar" <akbarbahar@unhas.ac.id>

Cc: Pauline Lanting <p.lanting@umcg.nl>, "Jens H.J. Bos" <h.j.bos@rug.nl>, "Rolf H. Sijmons" <r.h.sijmons@umcg.nl>, Eelko Hak <e.hak@rug.nl>, Bob Wilffert <b.wilffert@rug.nl>

Dear Dr. Bahar,

Thank you very much for resubmitting the modified version of the following manuscript:

Manuscript ID: jpm-977105

Type of manuscript: Article

Title: Impact of drug-gene-interaction, drug-drug-interaction, and drug-drug-gene-interaction on (es)citalopram therapy: the PharmLines initiative.

Authors: Muh. Akbar Bahar *, Pauline Lanting, Jens H.J. Bos, Rolf H. Sijmons, Eelko Hak, Bob Wilffert

Received: 9 October 2020

E-mails: akbarbahar@unhas.ac.id, p.lanting@umcg.nl, h.j.bos@rug.nl, r.h.sijmons@umcg.nl, e.hak@rug.nl, b.wilffert@rug.nl

Submitted to section: Pharmacogenetics,

<https://www.mdpi.com/journal/jpm/sections/pharmacogenetics>

Pharmacogenetics to Avoid Adverse Drug Reactions

https://www.mdpi.com/journal/jpm/special_issues/Pharmacogenetics_Adverse_Drug_Reactions

https://susy.mdpi.com/user/manuscripts/review_info/4c59937323f3834b5f04b67ce330446a

A member of the editorial office will be in touch with you soon regarding progress of the manuscript.

Kind regards,

MDPI

--

JPM Editorial Office

Postfach, CH-4020 Basel, Switzerland

Office: St. Alban-Anlage 66, CH-4052 Basel

Tel. +41 61 683 77 34 (office)

Fax +41 61 302 89 18 (office)

E-mail: jpm@mdpi.com

<https://www.mdpi.com/journal/jpm/>

*** This is an automatically generated email ***

[JPM] Manuscript ID: jpm-977105 - Revised Version Received

1 message

Daria Dou <daria.dou@mdpi.com>

Wed, Nov 11, 2020 at 1:34 PM

Reply-To: daria.dou@mdpi.com

To: "Muh. Akbar Bahar" <akbarbahar@unhas.ac.id>

Cc: Pauline Lanting <p.lanting@umcg.nl>, "Jens H.J. Bos" <h.j.bos@rug.nl>, "Rolf H. Sijmons" <r.h.sijmons@umcg.nl>, Eelko Hak <e.hak@rug.nl>, Bob Wilffert <b.wilffert@rug.nl>, JPM Editorial Office <jpm@mdpi.com>

Dear Dr. Bahar,

Thank you very much for providing the revised version of your paper:

Manuscript ID: jpm-977105

Type of manuscript: Article

Title: Impact of drug-gene-interaction, drug-drug-interaction, and drug-drug-gene-interaction on (es)citalopram therapy: the PharmLines initiative.

Authors: Muh. Akbar Bahar *, Pauline Lanting, Jens H.J. Bos, Rolf H. Sijmons, Eelko Hak, Bob Wilffert

Received: 9 October 2020

E-mails: akbarbahar@unhas.ac.id, p.lanting@umcg.nl, h.j.bos@rug.nl, r.h.sijmons@umcg.nl, e.hak@rug.nl, b.wilffert@rug.nl

Submitted to section: Pharmacogenetics,

<https://www.mdpi.com/journal/jpm/sections/pharmacogenetics>

Pharmacogenetics to Avoid Adverse Drug Reactions

https://www.mdpi.com/journal/jpm/special_issues/Pharmacogenetics_Adverse_Drug_Reactions

https://susy.mdpi.com/user/manuscripts/review_info/4c59937323f3834b5f04b67ce330446a

We will continue processing your paper and will keep you informed about the submission status.

Kind regards,

Ms. Daria Dou

E-Mail: daria.dou@mdpi.com

--

MDPI Tianjin Office 170 North Road, Room 1804, Block A, Lujiazui Financial Plaza, Hongqiao District, China

MDPI JPM Editorial Office

St. Alban-Anlage 66, 4052 Basel, Switzerland

E-Mail: jpm@mdpi.com

<http://www.mdpi.com/journal/jpm>

[JPM] Manuscript ID: jpm-977105 - Accepted for Publication

1 message

Daria Dou <daria.dou@mdpi.com>

Sat, Nov 14, 2020 at 10:35 AM

Reply-To: Daria Dou <daria.dou@mdpi.com>, JPM Editorial Office <jpm@mdpi.com>

To: "Muh. Akbar Bahar" <akbarbahar@unhas.ac.id>

Cc: Pauline Lanting <p.lanting@umcg.nl>, "Jens H.J. Bos" <h.j.bos@rug.nl>, "Rolf H. Sijmons" <r.h.sijmons@umcg.nl>, Eelko Hak <e.hak@rug.nl>, Bob Wilffert <b.wilffert@rug.nl>, JPM Editorial Office <jpm@mdpi.com>, Daria Dou <daria.dou@mdpi.com>

Dear Dr. Bahar,

We are pleased to inform you that the following paper has been officially accepted for publication:

Manuscript ID: jpm-977105

Type of manuscript: Article

Title: Impact of drug-gene-interaction, drug-drug-interaction, and drug-drug-gene-interaction on (es)citalopram therapy: the PharmLines initiative.

Authors: Muh. Akbar Bahar *, Pauline Lanting, Jens H.J. Bos, Rolf H. Sijmons, Eelko Hak, Bob Wilffert

Received: 9 October 2020

E-mails: akbarbahar@unhas.ac.id, p.lanting@umcg.nl, h.j.bos@rug.nl, r.h.sijmons@umcg.nl, e.hak@rug.nl, b.wilffert@rug.nl

Submitted to section: Pharmacogenetics,

<https://www.mdpi.com/journal/jpm/sections/pharmacogenetics>

Pharmacogenetics to Avoid Adverse Drug Reactions

https://www.mdpi.com/journal/jpm/special_issues/Pharmacogenetics_Adverse_Drug_Reactions

https://susy.mdpi.com/user/manuscripts/review_info/4c59937323f3834b5f04b67ce330446a

We will now make the final preparations for publication, then return the manuscript to you for your approval.

If, however, extensive English edits are required to your manuscript, we will need to return the paper requesting improvements throughout.

We encourage you to set up your profile at SciProfiles.com, MDPI's researcher network platform. Articles you publish with MDPI will be linked to your SciProfiles page, where colleagues and peers will be able to see all of your publications, citations, as well as your other academic contributions.

We also invite you to contribute to Encyclopedia (<https://encyclopedia.pub>), a scholarly platform providing accurate information about the latest research results. You can adapt parts of your paper to provide valuable reference information for others in the field.

Kind regards,
Ms. Jenifer Zhao
Assistant Editor

-
Ms. Jenifer Zhao
MDPI Branch Office, Beijing
Room 201, Building No. 4,
Zijin Digital Park, No. 18,
Nansi Avenue, Zhongguancun,
Haidian District, 100190 Beijing, China
Email: jenifer.zhao@mdpi.com
Skype:live:.cid.ded2b8e839c60a56

MDPI
St. Alban-Anlage 66
4052 Basel
Postfach, CH-4020 Basel
Switzerland

[JPM] Manuscript ID: jpm-977105; doi: 10.3390/jpm10040256. Paper has been published.

1 message

jpm@mdpi.com <jpm@mdpi.com>

Sat, Nov 28, 2020 at 2:17 PM

Reply-To: daria.dou@mdpi.com, jpm@mdpi.com

To: akbarbahar@unhas.ac.id, p.lanting@umcg.nl, h.j.bos@rug.nl, r.h.sijmons@umcg.nl, e.hak@rug.nl, b.wilffert@rug.nl

Cc: billing@mdpi.com, website@mdpi.com, jpm@mdpi.com, daria.dou@mdpi.com

Dear Authors,

We are pleased to inform you that your article "Impact of Drug-Gene-Interaction, Drug-Drug-Interaction, and Drug-Drug-Gene-Interaction on (es)Citalopram Therapy: The PharmLines Initiative" has been published in JPM as part of the Special Issue Pharmacogenetics to Avoid Adverse Drug Reactions and is available online:

Abstract: <https://www.mdpi.com/2075-4426/10/4/256>

PDF Version: <https://www.mdpi.com/2075-4426/10/4/256/pdf>

The meta data of your article, the manuscript files and a publication certificate are available here (only available to corresponding authors after login):

https://susy.mdpi.com/user/manuscripts/review_info/4c59937323f3834b5f04b67ce330446a

Special Issue:

https://www.mdpi.com/journal/jpm/special_issues/Pharmacogenetics_Adverse_Drug_Reactions

Please take a moment to check that everything is correct. You can reply to this email if there is a problem. Note that at this stage we will not accept further changes to the manuscript text.

To encourage open scientific discussions and increase the visibility of published articles, MDPI recently implemented interactive commenting and recommendation functionalities on all article webpages (side bar on the right). We encourage you to forward the article link to your colleagues and peers.

We encourage you to set up your profile at www.SciProfiles.com, MDPI's researcher network platform. Articles you publish with MDPI will be linked to your SciProfiles page, where colleagues and peers will be able to see all of your publications, citations, as well as your other academic contributions. Please also feel free to send us feedback on the platform that we can improve it quickly and make it useful for scientific communities.

You can also share the paper on various social networks by clicking the links on the article webpage. Alternatively, MDPI can post an announcement of your article on our Twitter channel (<https://twitter.com/MDPIOpenAccess>), please provide the doi number of the manuscript and a text of up to 117 characters with spaces to socialmedia@mdpi.com. Please note that our service Scitations.net will automatically notify authors cited in your article. For further paper promotion guidelines, please refer to the following link: https://res.mdpi.com/data/paper_promotion_tips.pdf

We would be happy to keep you updated about new issue releases of jpm. Please enter your e-mail address in the box at <https://www.mdpi.com/journal/jpm/toc-alert/> to receive notifications. After issue release, a version of your paper including the issue cover will be available to download from the article abstract page.

To order high quality reprints of your article in quantities of 25-1000, visit: <https://www.mdpi.com/2075-4426/10/4/256/reprints>

We support the multidisciplinary preprint platform /Preprints/, which permanently archives full text documents and datasets of working papers in all subject areas. Posting on the platform is entirely free of charge, and full details can be viewed at <http://www.preprints.org>.

We are dedicated to providing an outstanding publishing service, and we invite you to complete our author satisfaction survey <https://www.surveymonkey.com/r/authorfeedbackmdpi>. The survey contains 20 short questions and will only take a couple of minutes to complete.

Thank you for choosing JPM to publish your work, we look forward to receiving further contributions from your research group in the future.

Kind regards,

--
MDPI
Postfach, CH - 4020 Basel, Switzerland
Office: St. Alban-Anlage 66, 4052 Basel, Switzerland

Tel. +41 61 683 77 34
Fax: +41 61 302 89 18
E-mail: website@mdpi.com
<https://www.mdpi.com/>